Last updated on April 21, 2014 at 5:21 EDT

Immunotech Laboratories Appoints New Chief Financial Advisor to Strengthen Company’s Growth and International Expansion Plan

February 7, 2013

PASADENA, Calif., Feb. 7, 2013 /PRNewswire/ —

Immunotech Laboratories, Inc. (PINKSHEETS : IMMB )

Immunotech Laboratories, Inc., today announced the appointment of Mr. Valentin Dimitrov to the company Board of Directors as Chief Financial Advisor effective immediately.

Mr. Dimitrov (48) has an impressive professional history in the International Pharmaceutical World along with an impressive background in the formation and management of International Corporations, including the founding member and supervisory Board Chairman of the International Orthodox Bank – (present “Investbank” JSC).

Immunotech Director Bo Linton, further commented Mr. Dimitrov has an extensive knowledge of the Immunotech “IPF” patented technology and has worked alongside the company for several years, assisting with International awareness and potential Clinical Trial progression for the company’s Immunotherapy Treatments.

Immunotech President Harry Zhabilov commented, “We are very pleased to announce the appointment of Valentin to the Board of Directors and feel he will be a valuable member of our team, and significantly help accelerate the progression of the company towards FDA approval for the ‘IPF’ technology.”

The appointment of Mr. Dimitrov to Immunotech’s Board of Directors helps with the potential goal of upgrading the company to the NASDAQ exchange, where a minimum of 5 Board Members are required.

    About Valentin Lordanov Dimitrov

    Kliment Ohridski University      Master's degree - Social Pedagogics

    Kiev State University, Ukraine    Bachelor of International Diplomatic

    1995:                             University of National and World
                                      Economy - Sofia -Finances

    1999:                             Chemical-technological University -
                                      Sofia - Organic chemistry

    LANGUAGES:                        English -Fluent , Russian -fluent ,
                                      German - spoken

    2007-Current:                     "Vital-Fe" LTD - Distribution of
                                      bio-technology and pharmaceutical
                                      products - Director

    2003-Present                      "Bulgarian Association of Chemical
                                      and Fertilizer Industry" - Chairman

    2002-2003                         "Chimco Vienna" GmbH - Distributor of
                                      chemical and pharmaceutical products
                                      - Director

    1999-2002                         "CHIMCO" JSC, Vratza -Chemical
                                      production plant -Chairman of the
                                      Board of Directors

    1992-1998                         "Prima Gas" JSC - supply of natural
                                      gas - Director

    1995-1996                         "International Orthodox Bank" -
                                      (present "Investbank" JSC), Founder
                                      and member of the Supervisory Board

    1994-1995                         "Private Agricultural and Investment
                                      Bank" - Member of the Supervisory

    1990-1991                         "Pharmachem" JSC - pharmaceutical and
                                      chemical industry - Director of

Safe Harbor Statement: This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Immunotech Laboratories, Inc. from time to time in its periodic reports filed with the SEC. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Immunotech Laboratories believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Immunotech Laboratories to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, Immunotech Laboratories or any other person that the objectives and plans of Immunotech Laboratories will be achieved should not regard the forward-looking statements as a representation.

Company Contact:

Investor Relations:
The Nabors Group: 713-875-9200
E-mail: naborsgroup@yahoo.com

CSNNewswire – Be Seen

SOURCE Immunotech Laboratories, Inc.

Source: PR Newswire